Icatibant Amarox

Icatibant, the active ingredient in Icatibant Amarox, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats hereditary angioedema (HAE) attacks in patients who experience recurrent swelling episodes. GNH USA supplies Icatibant Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for bradykinin‑mediated angioedema, primarily hereditary angioedema. - Hereditary angioedema (HAE) attacks: rapidly reduces swelling, pain, and airway obstruction during acute episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Erythema: localized redness around the injection area. - Nausea: occasional feeling of queasiness. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: paradoxical swelling despite therapy. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: reduced platelet count observed in rare cases. - Severe hypersensitivity: rash, fever, or systemic symptoms.

Before initiating therapy with Icatibant, consider the following safety measures. - Renal impairment: assess kidney function and monitor for accumulation. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: risk unknown; discuss benefits and risks with a healthcare professional. - Concomitant ACE inhibitors: may increase bradykinin levels and risk of angioedema. - Known allergy to icatibant: contraindicated. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin pathway or cause overlapping side effects.

Major Interactions (Avoid): - ACE inhibitors: heightened risk of angioedema. - Other bradykinin B2 receptor antagonists: antagonistic pharmacodynamic effect. - Renin‑angiotensin system blockers: additive increase in bradykinin.

Moderate Interactions (Monitor Closely): - NSAIDs: may mask early signs of swelling. - Antihistamines: could reduce perceived efficacy. - Corticosteroids: generally safe but monitor for infection risk.